Researchers in China described a circular RNA (circRNA) therapeutic encoding human relaxin‑2 (cRLN2) as a first‑of‑its‑kind circRNA protein‑replacement strategy for liver fibrosis. The authors reported that the cRLN2 construct demonstrated high stability, low immunogenicity, and functional activity that reduced fibrotic markers in preclinical models. CircRNAs offer enhanced persistence compared with linear mRNAs, and the study showed improved tissue exposure and therapeutic effects in liver fibrosis models. The team outlined dosing, delivery considerations, and translational challenges including scalable manufacturing and safety profiling. If translated, circRNA protein replacement could expand the RNA therapeutic toolbox beyond gene silencing and traditional mRNA replacement, opening new avenues for chronic disease intervention.